Avacta Group PLC, a UK-based life sciences company, is set to announce its audited preliminary results for the year ended 31st December 2023 on 30th April 2024. The company will also deliver a live presentation via Investor Meet Company at 12:30 BST on the same day. The presentation is open to all existing and potential shareholders. Investors can sign up for free and submit questions in advance. The results presentation will also be available on the company's website.

Avacta Group PLC is focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The company has two divisions: Avacta Therapeutics, a clinical stage oncology biotech division developing novel, highly targeted cancer drugs, and Avacta Diagnostics, which aims to support healthcare professionals and broaden access to diagnostics. Avacta has two proprietary platforms, pre|CISION™ and Affimer®, which are utilized in developing highly targeted cancer drugs.

The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP), which is upregulated in most solid tumors compared with healthy tissues. This platform harnesses the tumor-specific protease to activate peptide drug conjugates and antibody/Affimer® drug conjugates in the tumor microenvironment, reducing systemic exposure and toxicity, and optimizing dosing for better patient outcomes.

For further information, interested parties can contact Avacta Group PLC directly or its appointed brokers.